Short Interest in Addex Therapeutics Ltd. Sponsored ADR (NASDAQ:ADXN) Expands By 137.6%

Addex Therapeutics Ltd. Sponsored ADR (NASDAQ:ADXN) was the target of a large growth in short interest in February. As of February 27th, there was short interest totaling 11,951 shares, a growth of 137.6% from the February 12th total of 5,030 shares. Currently, 1.1% of the company’s stock are sold short. Based on an average trading volume of 1,671 shares, the days-to-cover ratio is currently 7.2 days. Based on an average trading volume of 1,671 shares, the days-to-cover ratio is currently 7.2 days. Currently, 1.1% of the company’s stock are sold short.

Addex Therapeutics Price Performance

NASDAQ:ADXN opened at $6.88 on Friday. The firm has a 50-day moving average of $7.63 and a two-hundred day moving average of $8.27. The stock has a market cap of $8.46 million, a P/E ratio of -1.20 and a beta of 1.46. Addex Therapeutics has a 1-year low of $6.29 and a 1-year high of $12.05.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Addex Therapeutics in a report on Friday, January 9th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Addex Therapeutics currently has an average rating of “Sell”.

Addex Therapeutics Company Profile

Addex Therapeutics SA is a clinical-stage biopharmaceutical company specializing in the discovery and development of small-molecule allosteric modulators for central nervous system disorders. Founded in 1999 and headquartered in Geneva, Switzerland, with a U.S. research presence in Cambridge, Massachusetts, the company focuses on targeting metabotropic glutamate (mGlu) receptors and GABAB receptors to address unmet medical needs in neurology and psychiatry.

The company’s lead candidate, dipraglurant (ADX48621), is an mGlu5 negative allosteric modulator in clinical development for levodopa-induced dyskinesia in Parkinson’s disease.